GlaxoSmithKline (GSK) Canada will invest $28 million to further strengthen the company’s manufacturing facility in Mississauga, Ontario. The funds will enable facility improvements, equipment purchases and enhanced manufacturing capabilities. GSK’s Mississauga facility will also soon begin producing Voltaren®, a consumer health brand in Canada for pain relief.
“GSK has been part of the Mississauga life sciences sector for over 25 years and we are proud to contribute to the healthy and vibrant life sciences sector in this City, and this country,” said YS Hong, President of Canada Pharmaceuticals of GSK Canada.
The investment is part of Mississauga’s Economic Development Strategy to expand its economic development agenda, remain competitive, measure success, and attract innovative businesses to the city.
“I’m thrilled that GSK has decided to grow and expand their business here in Mississauga,” said Mississauga Mayor Bonnie Crombie. “Our city is proud to be home to Canada’s second largest Life Sciences cluster and today’s investment is proof that our strategy to support its growth is working. Together, we will take innovation all the way to commercialization in Mississauga.”
The city’s life sciences sector is the second largest in Canada by number of employees. Today Mississauga’s life sciences cluster is globally recognized as a significant economic driver.
“GSK has been a part of Mississauga’s strong and diverse life sciences cluster since 1989,” said Bonnie Brown, Director of Economic Development for the City of Mississauga. “The city appreciates GSK’s continued commitment and investment in Mississauga. Their presence in our business community helps present Mississauga on a global stage.”
